AKT1 and depressive symptom measurement: For instance, based on network pharmacology and target-pathway enrichment analysis, Zhang et al. constructed a "target–pathway–target" interaction map, identifying Protein Kinase B alpha (AKT1), Phosphoinositide-3-Kinase Regulatory Subunit 1 (PIK3R1), Nuclear Factor Kappa-B Subunit 1 (NFKB1), and RelA (p65) as core targets, which are linked to neurological diseases including depression[41].